Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Prilocaine hydrochloride 0.5%; Prilocaine hydrochloride 5 mg/mL; Prilocaine hydrochloride 0.5%
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Prilocaine hydrochloride 0.5%
0.5 %
Solution for injection
Active: Prilocaine hydrochloride 0.5% Excipient: Sodium chloride Sodium hydroxide Water for injection Active: Prilocaine hydrochloride 5 mg/mL Excipient: Hydrochloric acid as 2M solution for pH adjustment (pH 5 - 7) Methyl hydroxybenzoate Sodium chloride Sodium hydroxide as 2M solution for pH adjustment (pH 5 - 7) Water for injection Active: Prilocaine hydrochloride 0.5% Excipient: Hydrochloric acid Sodium chloride Sodium hydroxide Water for injection
Polyamp, 5mL Duofit., 10 dose units
Prescription
Prescription
Siegfried Evionnaz SA
The production of local or regional anaesthesia by the following techniques: · local infiltration · minor and major nerve blocks · epidural block · arthroscopy · intravenous regional anaesthesia
Package - Contents - Shelf Life: Polyamp, 5mL Duofit. - 10 dose units - 24 months from date of manufacture stored at or below 25°C - Vial, glass, single dose, 50mL - 1 dose units - 36 months from date of manufacture stored at or below 25°C - Vial, glass, single dose, 50mL - 5 dose units - 36 months from date of manufacture stored at or below 25°C
1969-12-31
C ITANEST Data Sheet NEW ZEALAND DATA SHEET 1. PRODUCT NAME C ITANEST ® solution for injection Prilocaine hydrochloride 0.5%, 2.0% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Citanest contains 5mg or 20mg of prilocaine hydrochloride per 1mL For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Citanest solution for injection is a sterile, isotonic aqueous solution. The pH of the solution is 5.0-7.0. The single dose vials and Polyamps® are free from preservatives and are intended for single use only. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Citanest solutions are indicated for the production of local or regional anaesthesia by the following techniques: • local infiltration • minor and major nerve blocks • epidural block • arthroscopy • intravenous regional anaesthesia. 4.2 DOSE AND METHOD OF ADMINISTRATION Care should be taken to prevent toxic reactions by avoiding intravascular injection. Careful aspiration before and during the injection is recommended. When a large dose is to be injected, e.g. in epidural block, a test dose of 3-5 mL of prilocaine containing adrenaline is recommended. An accidental intravascular injection may be recognised by a temporary increase in heart rate. The main dose should be injected slowly, at a rate of 100-200 mg/min, or in incremental doses, while keeping in constant verbal contact with the patient. If toxic symptoms occur, the injection should be stopped immediately. In general, surgical anaesthesia (e.g. epidural administration) requires the use of the higher concentrations and doses. When a less intense block is required, the use of a lower concentration is indicated. The volume of local anaesthetic used will affect the extent of spread of anaesthesia. For a more prolonged effect, an indwelling catheter, through which the local anaesthetic may be injected, can be used. This technique is common in epidural anaesthesia and may also be used in brachial plexus anaesthesia and interpleural analgesia. C ITANEST Data Sheet Copyright 2 The following Read the complete document